The FDA issued warning letters to 21 compounding pharmacies across 14 states for quality violations in their semaglutide and tirzepatide products, the agency announced on March 7. The enforcement action, the largest coordinated action against compounding pharmacies in FDA history, cited problems ranging from incorrect drug potency to failures in sterility testing and unsanitary manufacturing conditions.
FDA Commissioner Robert Califf said the warning letters represent an escalation in the agency's oversight of compounded GLP-1 products. "We have identified serious quality concerns that put patients at risk," Dr. Califf stated. "Compounded drugs are not FDA-approved, and these findings demonstrate why that approval process matters."
What the Inspections Found
FDA investigators conducted inspections at 38 compounding pharmacies between October 2025 and February 2026 as part of a targeted enforcement initiative. Of those 38, 21 received warning letters for significant violations [1].
The most common findings included:
Potency failures were found at 16 of the 21 pharmacies. Independent lab testing of compounded semaglutide vials showed actual drug content ranging from 62% to 143% of the labeled amount. Under-potent products may not produce the expected therapeutic effect. Over-potent products increase the risk of serious side effects, particularly severe nausea, vomiting, and hypoglycemia [1].
Sterility violations were cited at 12 pharmacies. Inspectors found environmental monitoring failures, inadequate cleanroom procedures, and in three cases, bacterial contamination detected in finished vials. Injectable medications that are not sterile can cause serious infections, including potentially fatal bloodstream infections.
Labeling deficiencies appeared at 9 pharmacies, including vials that did not specify the semaglutide salt form used, vials with incorrect beyond-use dating, and products marketed with claims about FDA approval or equivalence to Wegovy or Ozempic.
The Compounding Pharmacy Debate
Compounding pharmacies have played a controversial role in the GLP-1 market. When Wegovy and Ozempic faced persistent shortages beginning in 2023, compounding pharmacies stepped in to fill the gap, producing semaglutide products at prices significantly lower than the brand-name drugs, often $200-400 per month compared to $1,300 or more for Wegovy.
Patients turned to these products in large numbers. The National Community Pharmacists Association estimated that compounding pharmacies dispensed approximately 2.5 million semaglutide prescriptions in 2025, representing roughly 15% of total semaglutide prescriptions in the United States [2].
The FDA removed semaglutide from its drug shortage list in February 2025, which, under the agency's interpretation, ended the legal basis for compounding pharmacies to produce copies. However, the Outsourcing Facilities Association and several individual pharmacies have challenged this determination in court, and a federal judge in Texas issued a preliminary injunction in October 2025 allowing certain 503B outsourcing facilities to continue production during the litigation [3].
Patient Safety Concerns
The warning letters highlight real safety risks that patients using compounded GLP-1 products should understand. Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School who studies supplement and compounding pharmacy safety, said the potency findings are particularly concerning.
"A patient who receives a vial that is 62% of the labeled potency is essentially being undertreated. They may not lose weight, they may think the drug doesn't work, and their prescriber may increase the dose, which creates additional risk if the next vial happens to be over-potent," Dr. Cohen explained.
The sterility concerns are more immediately dangerous. In 2012, a contaminated compounded steroid injection produced by the New England Compounding Center caused a fungal meningitis outbreak that killed 76 people and sickened more than 750 [4]. While no adverse events of that magnitude have been linked to compounded semaglutide, the FDA's findings suggest that the sterility controls at some facilities are inadequate.
What the Warning Letters Require
Warning letters give pharmacies 15 business days to respond with a corrective action plan. If the FDA determines the response is inadequate, it can pursue injunctions, seizures, or criminal prosecution.
The 21 pharmacies that received letters must immediately cease distribution of any products found to be adulterated, implement corrective actions for all cited violations, and submit to follow-up inspections. Three pharmacies voluntarily ceased operations upon receiving their letters [1].
The FDA has also referred cases to the Department of Justice for potential criminal charges at four pharmacies where inspectors found evidence of intentional falsification of quality testing records.
How Patients Can Protect Themselves
Patients currently using compounded semaglutide or tirzepatide should take several steps to assess their risk.
First, check whether your pharmacy received a warning letter. The FDA publishes all warning letters on its website, searchable by company name [5]. If your pharmacy is on the list, stop using the product and contact your prescriber immediately.
Second, ask your compounding pharmacy for a certificate of analysis from an independent third-party lab, not just their own internal testing. Reputable pharmacies should be willing and able to provide this documentation.
Third, discuss FDA-approved alternatives with your prescriber. With Wegovy, Ozempic, and Zepbound supply stabilizing, the availability of brand-name products has improved significantly. Patient assistance programs and savings cards may reduce costs.
Dr. Cohen offered a blunt assessment. "If you are using a compounded GLP-1 product, you are accepting a level of risk that you would not accept with an FDA-approved medication. That doesn't mean every compounded product is dangerous, but you cannot verify quality the way you can with an approved drug."
Sources
- FDA. "Warning Letters to Compounding Pharmacies: Semaglutide and Tirzepatide Products." March 2026.
- National Community Pharmacists Association. "Compounding Market Report 2025." January 2026.
- Outsourcing Facilities Association v. FDA, Case No. 4:25-cv-00893 (S.D. Tex. 2025).
- CDC. "Multistate Outbreak of Fungal Meningitis and Other Infections." 2012.
- FDA Warning Letters Database.